Redefining CDMO Partnerships Through EnzeneX™ 2.0 and Fully-Connected Continuous Manufacturing™

Redefining CDMO Partnerships Through EnzeneX™ 2.0 and Fully-Connected Continuous Manufacturing™

In this video, Himanshu shares Enzene’s journey from a biosimilar development company to a Continuously Innovative and Development Manufacturing Organization (CIDMO). He discusses how Enzene is leveraging continuous manufacturing to improve productivity, reduce production costs, and expand access to life-saving medicines. He also outlines the company’s vision for the future, including the integration of advanced process analytical technologies to enable data-driven, automated biomanufacturing.

Key topics covered:

• Enzene’s transformation of biologics manufacturing through continuous processing and innovation.
• How Enzene’s Fully Connected Continuous Manufacturing (FCCM™) technology improves efficiency, increases volumetric productivity, and reduces manufacturing costs.
• The potential of advanced manufacturing technologies to improve access to biologic medicines by enhancing operational efficiency and lowering production costs.
• The role of process analytical technologies (PAT) and real-time monitoring in enabling the next generation of automated biomanufacturing.
• Enzene’s long-term vision for a self-governing, data-driven manufacturing ecosystem that enhances quality, scalability, and accessibility.

Speakers

Himanshu Gadgil CEO

Himanshu Gadgil, PhD brings with him 24 years of experience in the pharmaceutical industry. He is the Chief Executive Officer at Enzene Biosciences Ltd. presiding over all business functions of the company. Under his leadership, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company. Previously, as Sr. Vice President at Intas Pharmaceutical Ltd., he revitalized the commercial product pipeline, launching several biosimilar products globally. During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation where he pioneered development of QBD enabling multi-attribute methodologies for biopharmaceutical characterization. Himanshu holds a PhD in Biochemistry from University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.